Evoke underscores committment to patients after FDA update on domperidone

Evoke Pharma (EVOK) underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update regarding domperidone supply. As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI is uniquely positioned to address the ongoing needs of patients facing challenges with alternative therapies. FDA’s recent announcement regarding the discontinuation of domperidone supply further highlights the urgent need for safe, effective, and accessible therapies like GIMOTI for patients struggling with gastroparesis